Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 10;13:5973. doi: 10.1038/s41467-022-33671-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Survival (Kaplan–Meier curve) of Cre-ER (n = 7) and Cre-ER;Arih1^fl/fl mice (n = 6) intraperitoneally injected with tamoxifen for five successive days and rested for 5 days followed by intraperitoneal injection with HSV-1. b ELISA analysis of IFN-β and IL-6 in the sera of Cre-ER (n = 5) and Cre-ER;Arih1^fl/fl mice (n = 5) treated as in (a) and intraperitoneally injected with HSV-1 for 12 h. c, d qRT-PCR analysis of Ifnb, Ccl5, and UL30 mRNA in the spleen (c) or brain (d) from Cre-ER (n = 6) and Cre-ER;Arih1^fl/fl mice (n = 6) treated as in (a) and intraperitoneally injected with HSV-1 for 3 days. e Plaque assays analyzing HSV-1 titers in the spleen or brain from Cre-ER (n = 6) and Cre-ER;Arih1^fl/fl mice (n = 6) treated as in (c). f Hematoxylin-eosin (HE) staining of brain sections of Cre-ER (n = 4) and Cre-ER;Arih1^fl/fl mice (n = 4) treated as in (a) followed by intracerebral injection of HSV-1 for 3 days. g Survival of Arih1^fl/fl (n = 10) and Lyz2-Cre;Arih1^fl/fl mice (n = 10) intraperitoneally injected with HSV-1. h ELISA analysis of IFN-β and IL-6 in the sera of Arih1^fl/fl (n = 7) and Lyz2-Cre;Arih1^fl/fl mice (n = 6) intraperitoneally injected with HSV-1 for 12 h. i, j qRT-PCR analysis of Ifnb, Ccl5, and UL30 mRNA in the spleen and brain from Arih1^fl/fl (n = 5) and Lyz2-Cre;Arih1^fl/fl mice (n = 5) intraperitoneally injected with HSV-1 for 3 days. k Plaque assays analyzing HSV-1 titers in the spleen or brain from Arih1^fl/fl (n = 5) and Lyz2-Cre Arih1^fl/fl mice (n = 5) intraperitoneally injected with HSV-1 for 3 days. l HE staining of brain sections of Arih1^fl/fl (n = 4) and Lyz2-Cre Arih1^fl/fl mice (n = 4) intracerebrally injected with HSV-1 respectively for 3 days. 1 × 10⁷ PFU and 1 × 10⁶ PFU HSV-1 were injected with per mice in (a–e, g–k, f). l respectively. Data are of combined two independent experiments (a, g) or representative of two independent experiments (b–f, h–l). Graphs show mean ± S.D. (n = 5 for (b, i–k), or n = 6 for (c–e), or n = 7 and 6 for (h), biologically independent experiments). Statistical significance was determined using two-tailed Student’s t tests in (b–e, h–k). Source data are provided as a Source Data file.